GSK2126458 Chemical Structure
BEZ235 (NVP-BEZ235)is a dual ATP-competitive phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor of p110α, p110γ, p110δ and p110β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM,respectively.
Deforolimus (Ridaforolimus) is a small-molecule inhibitor of mTOR.
Perifosine is an Akt inhibitor. the antiproliferative properties of perifosine with an IC50 of 0.6–8.9 µM.
PI-103 is a potent, cell-permeable, ATP-competitive PI3K family member inhibitor with IC50 of 2, 8, 20, 26, 48, 83, 88, 150 nM for DNA-PK, p110α, mTORC1, PI3-KC2β, p110δ, mTORC2, p110β, and p110γ, respectively.
Rapamycin also known as Sirolimus & Rapamune is an mTOR inhibitor. Rapamycin Sirolimus inhibits cell motility by suppression of mTOR-mediated pathways.
Temsirolimus (Torisel) is a mTOR inhibitor.
Inhibitor of Class I PI3 Kinase,p110a IC50=0.003uM,U87MG IC50=0.95μM.
ZSTK474 is an inhibitor of PI3K γ(IC50 at 6 nM).
LY294002 is a PI3k inhibitor (cell IC50 about 10 μM) and a casein kinase II inhibitor.
XL147 is a selective inhibitor of Class I PI3K isoforms.
GSK2126458 is a highly potent PI3K and mTOR inhibitor with an app Ki of 19 pM for PI3K. In vivo, GSK2126458 showed anti-tumor activity in both pharmacodynamic and tumor growth efficacy models. In cell, in good agreement with the inhibition of potent PI3K. GSK2126458 reduced the phosphorylated AKT, p70S6K contents in a dose and time dependent way, as well as the prevention of PRAS40 and ERK. The IC50 of GSK2126458 is 2 nM for pAKT in the HCC1954 breast carcinoma cell line. In various human tumor cells, GSK2126458 had a width of inhibitory activity for potent cell growth and induced cell death. Notably, GSK2126458 acted mainly by not induction of apoptosis but cell cycle arrest, particularly in G1-phase. [1][2]
| Molecular Weight (WM): | 505.5 |
|---|---|
| Formula: | C25H17F2N5O3S |
| CAS No.: | 1086062-66-9 |
| Synonyms: |
N/A
|
| Dissolve in (25°C): | DMSO ≥101mg/mL |
| Water <1mg/mL | |
| Ethanol <1mg/mL | |
| Storage: | 2 years-20°CPowder |
| 1 week-4°Cin DMSO | |
| 1 month-80°in DMSO |
A collection of 864 bioactive compounds
A collection of 481 inhibitors
A collection of 194 kinase inhibitors
A collection of 85 tyrosine kinase inhibitors.
A collection of 426 FDA approved drugs
A collection of 139 natural products
A collection of 40 chemotherapeutic agents
A unique collection of 17 small molecule modulators
A unique collection of 47 small molecule inhibitors
A unique collection of 63 GPCR small molecules

After starved in serum-free medium for 24h,A549 cells incubated with the indicated concentrations of GSK2126458 for 3h,followed by 20-minute stimolation of 100ng/ml EGF. |
After starved in serum-free medium for 24h,A549 cells incubated with the indicated concentrations of GSK2126458 for 3h,followed by 20-minute stimolation of 100ng/ml EGF.
Data independently produced by Dr. Zhang of Tianjin Medical University GSK2126458 purchased from Selleck
Keywords:buy GSK2126458 | GSK2126458 supplier | purchase GSK2126458 | GSK2126458 cost | GSK2126458 manufacturer | order GSK2126458 | GSK2126458 distributor